GLYCOPYRROLATE (GLYCOPYRROLATE)
- General anesthesia adjunct
- Vagal reflex bradycardia
0.4 mg/2 mL (0.2 mg/mL) intravenous syringe
- Dosage information is not available
0.6 mg/3 mL (0.2 mg/mL) intravenous syringe
- Dosage information is not available
1 mg/5 mL (0.2 mg/mL) intravenous syringe
- Dosage information is not available
- None
Contraindicated
- None
Severe
Moderate
- trifluoperazine
- thioridazine
- Promethegan
- promethazine-phenylephrine
- promethazine-phenyleph-codeine
- promethazine-DM
- promethazine-codeine
- Promethazine Vc-codeine
- Promethazine Vc
- promethazine
- prochlorperazine maleate
- prochlorperazine Edisylate
- prochlorperazine
- Phenergan
- Phenadoz
- perphenazine-amitriptyline
- perphenazine
- Loxitane
- loxapine succinate
- loxapine
- haloperidol lactate
- haloperidol decanoate
- haloperidol
- Haldol Decanoate
- Haldol
- fluphenazine HCl
- fluphenazine decanoate
- Compro
- Compazine
- chlorpromazine
- Adasuve
- Angle-closure glaucoma
- Hemorrhagic shock
- Paralytic ileus
- Pyloroduodenal obstruction
- Severe ulcerative colitis
- Sjogren's syndrome
- Toxic megacolon
Contraindicated
- Autonomic dysreflexia
- Benign prostatic hyperplasia
- Bladder outflow obstruction
- Gastric ulcer
- Gastrointestinal obstruction
- Myasthenia gravis
- Toxin-mediated diarrhea
- Ulcerative colitis
- Urinary retention
- Urinary tract obstructive uropathy
Severe
Moderate
- Chronic heart failure
- Coronary artery disease
GLYCOPYRROLATE (GLYCOPYRROLATE)
- General anesthesia adjunct
- Vagal reflex bradycardia
- None
- Constipation
- Decreased sweating
- Nasal congestion
- Vomiting
- Xerostomia
More Frequent
Severe
Less Severe
- None
- Breast milk flow decreased
- Urinary hesitancy
- Urinary retention
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Abdominal distension
- Acute confusion
- Acute respiratory insufficiency
- Anaphylaxis
- Cardiac arrest
- Cardiac arrhythmia
- Dehydration
- Heart block
- Heat stroke
- Hypersensitivity drug reaction
- Hypertension
- Hypotension
- Ileus
- Injection site sequelae
- Ocular hypertension
- Pneumonia
- Seizure disorder
- Skin rash
- Tachycardia
- Urticaria
Less Severe
- Acute abdominal pain
- Agitation
- Blurred vision
- Cheilosis
- Cycloplegia
- Dizziness
- Drowsy
- Dry nose
- Dry skin
- Dysgeusia
- Erectile dysfunction
- Fever
- Flatulence
- Flushing
- General weakness
- Headache disorder
- Impulse control disorder
- Insomnia
- Irritability
- Loss of taste
- Mood changes
- Mydriasis
- Nausea
- Nervousness
- Nystagmus
- Pain
- Pallor
- Palpitations
- Photophobia
- Pruritus of skin
- Sinusitis
- Thick bronchial secretions
- Upper respiratory infection
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Glycopyrrolate (Inj,Oral)
Safety and efficacy not established age < 3 years.
- 1 Day – 3 Years
- Safety and efficacy not established age < 3 years.
Glycopyrrolate
- Severity Level:
2
- Additional Notes: Insuff human data avail; animal data do not sug risk
Contraindicated
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Precaution Exists
Glycopyrrolate
May inhibit lactation; unlikely to be excreted.
General | Excretion Potential | Effect on Infant | Notes |
Evaluate use carefully | Unknown | Not known; no or inclusive data | May inhibit lactation; unlikely to be excreted. |
No Known Risk
None
General | Excretion Potential | Effect on Infant | Notes |
None |
Contraindicated
None
Precaution Exists
Glycopyrrolate
Neuro/Psych-Anticholinergic effects may cause sedation, worsen cognitive impairment and increase fall risk. Cardiovascular-May cause orthostatic hypotension at higher doses. Gastrointestinal-May cause or worsen pre-existing constipation. Genitourinary-Best avoided in patients with urinary retention from any cause.
Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: Y
No Known Risk
None
- None
Vagal reflex bradycardia | |
R00.1 | Bradycardia, unspecified |
0-9 | A-Z |
---|---|
R00.1 | Bradycardia, unspecified |